[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596575":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":43,"collaborators":47,"id":51,"slug":26,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":23,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":26,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":26,"overallStatus":69,"whyStopped":26,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University of Malaga","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention","EXPERIMENTAL","A treatment with whole body red light therapy (NovoTHOR®) will be carried out",[13],"Device: PBM",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","A placebo whole body red light will be carried out",[19],"Other: Placebo PBM",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","PBM","A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo PBM","A placebo whole body red light will be carried out during 20 minutes",[15],[32],{"facility":33,"status":26,"city":34,"state":26,"zip":26,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":26},"Dr","Granada","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],-3.60667,37.18817,{"lat":41,"lon":40},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Daniel Aguilar Nunez","danunez",[48],{"name":49,"class":50},"clinical professor","UNKNOWN","100596575",false,"NCT07047248","Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial","Inclusion Criteria:\n\n* Adults aged 30 to 70 years.\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the American Diabetes Association (ADA) criteria.\n* HbA1c levels between 6.5% and 10% at screening.\n* Stable diabetes management regimen (medications and lifestyle) for at least three months prior to enrollment\n\nExclusion Criteria:\n\n* Presence of severe diabetic complications (e.g., end-stage renal disease, proliferative diabetic retinopathy).\n* History of photosensitivity or medical conditions exacerbated by light exposure.\n* Use of medications or supplements known to significantly alter glucose metabolism, other than current stable diabetes management.\n* Pregnant or lactating women.",true,"ALL","30 Years","70 Years",{"count":61,"type":62},44,"ESTIMATED","INTERVENTIONAL",[65],"NA","The development of an integral and global treatment to improve the quality of life in those withType II Diabetes Patients is challenging, thus a whole body Photobiomodulation (PBM) therapy program is proposed as an effective option.",[68],"Type II Diabetes Mellitus","NOT_YET_RECRUITING","2025-06-27",{"date":72,"type":73},"2025-07-02","ACTUAL",{"date":75,"type":62},"2025-08-30",{"date":77,"type":62},"2026-01-30",{"name":5,"class":6},1]